GLP1R and type 2 diabetes mellitus: Thus, this post-hoc analysis represents the first demonstration of substantial reductions in HbA1c and body weight achieved with the novel once-weekly dual GIP/GLP-1 RA tirzepatide in adult GADA-positive patients who were previously diagnosed with T2D and who are likely affected by LADA.